Short Interest in Fresenius Medical Care AG (NYSE:FMS) Grows By 63.6%

Fresenius Medical Care AG (NYSE:FMSGet Free Report) saw a significant growth in short interest in March. As of March 15th, there was short interest totalling 1,330,000 shares, a growth of 63.6% from the February 29th total of 813,000 shares. Based on an average daily trading volume, of 438,900 shares, the short-interest ratio is presently 3.0 days.

Institutional Trading of Fresenius Medical Care

Institutional investors have recently bought and sold shares of the company. Clear Street Markets LLC bought a new stake in Fresenius Medical Care during the fourth quarter valued at $28,000. Bruce G. Allen Investments LLC bought a new position in shares of Fresenius Medical Care during the 4th quarter worth about $31,000. Hartford Financial Management Inc. boosted its position in shares of Fresenius Medical Care by 98.8% during the 4th quarter. Hartford Financial Management Inc. now owns 1,688 shares of the company’s stock worth $35,000 after purchasing an additional 839 shares in the last quarter. Tower Research Capital LLC TRC boosted its position in shares of Fresenius Medical Care by 349.3% during the 4th quarter. Tower Research Capital LLC TRC now owns 2,314 shares of the company’s stock worth $48,000 after purchasing an additional 1,799 shares in the last quarter. Finally, Atlas Capital Advisors LLC bought a new position in shares of Fresenius Medical Care during the 4th quarter worth about $55,000. Institutional investors own 8.25% of the company’s stock.

Fresenius Medical Care Stock Performance

NYSE FMS opened at $19.28 on Friday. The company has a quick ratio of 1.07, a current ratio of 1.42 and a debt-to-equity ratio of 0.47. The company has a market capitalization of $11.31 billion, a price-to-earnings ratio of 20.96, a PEG ratio of 0.93 and a beta of 1.00. The stock has a fifty day simple moving average of $19.74 and a 200 day simple moving average of $19.80. Fresenius Medical Care has a twelve month low of $16.37 and a twelve month high of $27.72.

Fresenius Medical Care (NYSE:FMSGet Free Report) last issued its quarterly earnings results on Tuesday, February 20th. The company reported $0.47 EPS for the quarter, beating analysts’ consensus estimates of $0.36 by $0.11. The business had revenue of $5.37 billion for the quarter, compared to analysts’ expectations of $5.32 billion. Fresenius Medical Care had a net margin of 2.56% and a return on equity of 4.99%. Sell-side analysts expect that Fresenius Medical Care will post 1.53 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the stock. StockNews.com upgraded shares of Fresenius Medical Care from a “hold” rating to a “strong-buy” rating in a report on Wednesday, February 21st. Morgan Stanley downgraded Fresenius Medical Care from an “equal weight” rating to an “underweight” rating in a report on Monday, January 8th. One analyst has rated the stock with a sell rating, five have assigned a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Fresenius Medical Care presently has a consensus rating of “Hold” and a consensus target price of $32.25.

Read Our Latest Report on Fresenius Medical Care

About Fresenius Medical Care

(Get Free Report)

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.

See Also

Receive News & Ratings for Fresenius Medical Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care and related companies with MarketBeat.com's FREE daily email newsletter.